Recercat. Dipósit de la Recerca de Catalunya
Publication
Artículo científico (JournalArticle)
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial
Angiogenesis inhibitors; Immune checkpoint inhibitors; Immunotherapy, Inhibidors de l'angiogènesi; Inhibidors de punts de control immunitari; Immunoteràpia, Inhibidores de la angiogénesis; Inhibidores de puntos de control inmunitario; Inmunoterapia, Background: The use of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) remains limited to tumors harboring microsatellite instability (MSI); however, a subset of microsatellite stable (MSS) tumors features an MSI-like phenotype that could predict responses to ICIs combined with anti-angiogenesis agents.
Patients and methods: In this single-arm phase II trial, 45 mCRC patients with a positive tumoral MSI-like gene expression signature (GES) progressing to at least one chemotherapy regimen were recruited from seven European sites within the MoTriColor framework. Of these, 24 and 21 were MSI and MSS, respectively, by standard assays. Patients received intravenous atezolizumab (1200 mg) plus bevacizumab (7.5 mg/kg) infusions in 21-day cycles until progression, unacceptable toxicity, or consent withdrawal. The main outcome measure was the objective response rate (ORR, RECIST 1.1).
Results: The median (interquartile range) age of participants was 63 (58-73) years, 51.1% were male, 60.0% had right-sided tumors, and 31.1% had liver metastases. The ORR in the whole (MSI-like) sample was 38.6% [95% confidence interval (CI) 24.4% to 54.5%]. Among patients with MSI and MSS tumors, the ORR was 65.2% (95% CI 42.7% to 83.6%) and 9.5% (95% CI 1.2% to 30.4%), respectively. In the MSS subgroup without liver metastasis, the ORR was 15.4% (95% CI 1.9% to 45.4%). Overall median progression-free survival was 6.4 (95% CI 4.1-21.2) months (23.2 and 4.0 months in patients with MSI and MSS tumors, respectively). Grade ≥3 adverse events related to atezolizumab and bevacizumab occurred in 5 (11.1%) and 10 patients (22.2%), respectively. There were two grade 5 adverse events, of which one (colonic hemorrhage) was related to bevacizumab.
Conclusions: MSI-like GES does not identify a population with higher sensitivity to immune checkpoint plus angiogenesis inhibition. However, responses are promising in patients with MSI tumors and, to a lesser extent, in patients without liver metastasis regardless of MSI status., This work was supported by the European Commission’s Horizon 2020 Research and Innovation Program [grant number 635342]; the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Program (TARGET) [grant number 101020342] to AB; the AIRC under 5 per Mille 2018 program for principal investigator AB [grant number 21091]; the FPRC under 5 per Mille Ministerio della Salute 2022 CARESS for SA; the IMI contract ID: 101007937 PERSIST-SEQ (to AB); the AIRC under IG 2023 for principal investigator AB [grant number 28922] and SA [grant number 29286]; the Italian Ministry of Health—Ricerca Corrente 2025 (to SA); and PRIN 2022—Prot. 2022CHB9BA financed by the European Union—Next Generation EU (to AB). In addition, F. Hoffmann-La Roche Ltd. (no grant number) provided the study medication and partial funding for logistical issues. The funders did not have any direct corporate role in the design, analysis, interpretation of results, or preparation of the manuscript.
Project:
EC / H2020 635342
,
EC / H2020 101020342